Adaptive Biotech
Bookmark
ShareCopied to clipboardAdaptive Biotech is a company. It is a public company in Seattle, the United States. It was founded in 2009 and its current CEO is Chad M. Robins. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Seattle
- country: United States
- employees: 619 people
- revenues: 179M $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 2009
- CEO: Chad M. Robins
- CEO approval: 55 %
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Adaptive Biotech:
Dataset of stocks from Adaptive Biotech:
Adaptive Biotech is one of the companies in the United States, companies in Biotechnology, companies in Health Care, companies in Seattle and 3,456,808 companies in our database.
Talking Points
- Powering the Age of Immune Medicine
- Adaptive Biotechnologies is harnessing the immune system to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine.
- Adaptive Biotechnologies is a pioneer & leader in immune-driven medicine. We aim to improve lives by learning from the wisdom of our adaptive immune systems.
- Every immune system has a story to tell; the key is knowing how to listen. | Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people's lives by learning from the wisdom of their adaptive immune systems. Adaptive's proprietary immune profiling platform reveals and translates ...
- Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
- Career Listings
- Adaptive Biotechnologies is looking for curious, passionate people with a shared desire to advance science and healthcare in their career.